{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:58:23Z","timestamp":1789689503074,"version":"4.0.1"},"reference-count":31,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,12]]},"abstract":"<jats:sec>\n                    <jats:title>abstract<\/jats:title>\n                    <jats:p>We assessed the overall survival (OS) impact of time to relapse (TTR) in multinational cohorts with independent observational and randomized validation. Patients with nMTCL with frontline complete response were assigned to TTR12 (\u226412 months) or without TTR12 based on time to progression or next therapy. OS analyses included modified landmark (m-LM), standard landmark (s-LM), and time-dependent Cox (td-Cox), adjusting for age, histology, and prognostic index for T-cell lymphoma (PIT) score. Across 452 patients, 165 (36.5%) had TTR12, 181 (40%) relapsed at \u226512 months, and 106 (23.5%) remained relapse-free. TTR12 conferred worse OS using m-LM (hazard ratio [HR], 2.14; 95% confidence interval [CI], 1.58-2.90; P&amp;lt; .001), s-LM (HR, 1.92; 95% CI, 1.39-2.66; P&amp;lt; .001); and td-Cox (HR, 5.81; 95% CI, 2.94-11.46; P&amp;lt; .001). Results were consistent in the independent validation cohorts. TTR12 consistently conferred worse OS irrespective of frontline stem cell transplantation or PIT score, in peripheral T-cell lymphoma, not otherwise specified (m-LM: HR, 2.32; 95% CI, 1.51-3.55; P&amp;lt; .001; s-LM: HR, 2.10; 95% CI, 1.33-3.31; P = .001), anaplastic large cell lymphoma (m-LM: HR, 3.34; 95% CI, 1.18-9.50; P = .023; s-LM: HR, 2.96; 95% CI, 1.02-8.81; P = .046), and angioimmunoblastic T-cell\/T follicular helper cell lymphoma (m-LM only: HR, 1.92; 95% CI, 1.15-3.21; P = .013). Second-line novel therapies improved OS (second-line start to death) vs chemotherapy in TTR12 only (HR, 0.60; 95% CI, 0.37-0.97; P = .038; without TTR12: HR, 0.82; 95% CI, 0.51-1.32; P = .407). TTR12 serves as a prognostic and potential OS surrogate marker, supporting stratification of new risk groups and need for their differential treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030149","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:06:25Z","timestamp":1764943585000},"page":"755-767","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6906-0568","authenticated-orcid":false,"given":"Mark N.","family":"Sorial","sequence":"first","affiliation":[{"name":"1Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Jon and Jo Ann Hagler Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Malpica Castillo","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-2578","authenticated-orcid":false,"given":"Carlos","family":"Chiattone","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Santa Casa Medicine School, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3325-8107","authenticated-orcid":false,"given":"Edith","family":"Julia","sequence":"additional","affiliation":[{"name":"5Hematology Department, H\u00f4pital Lyon Sud, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-7510","authenticated-orcid":false,"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[{"name":"5Hematology Department, H\u00f4pital Lyon Sud, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-5271","authenticated-orcid":false,"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-5170","authenticated-orcid":false,"given":"Robert","family":"Stuver","sequence":"additional","affiliation":[{"name":"7Lymphoma Service, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"8Lymphoma Program, Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA"},{"name":"9Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[{"name":"10CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9947-7065","authenticated-orcid":false,"given":"Hasmukh","family":"Jain","sequence":"additional","affiliation":[{"name":"11Hematolymphoid Unit, Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"12Sir Peter MacCallum Department of Hematology and Oncology and University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7843-3162","authenticated-orcid":false,"given":"Francine","family":"Foss","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"14IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia Ser\u00e0gnoli, Bologna, Italy"},{"name":"15Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0796-9137","authenticated-orcid":false,"given":"Takeshi","family":"Okatani","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"17Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4657-7318","authenticated-orcid":false,"given":"Estelle","family":"Verburgh","sequence":"additional","affiliation":[{"name":"18Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2919-4924","authenticated-orcid":false,"given":"Mubarak","family":"Al-Mansour","sequence":"additional","affiliation":[{"name":"19Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-3871","authenticated-orcid":false,"given":"Maria Elena","family":"Cabrera","sequence":"additional","affiliation":[{"name":"20Hematology Department, Hospital del Salvador, University of Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6250-048X","authenticated-orcid":false,"given":"Govind","family":"Bhagat","sequence":"additional","affiliation":[{"name":"21Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Shen","sequence":"additional","affiliation":[{"name":"22Evidence Generation and Advanced Analytics, Biogen Digital Health, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1566-9308","authenticated-orcid":false,"given":"Salvia","family":"Jain","sequence":"additional","affiliation":[{"name":"2Jon and Jo Ann Hagler Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"9Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"23Broad Institute of Harvard and MIT, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2026030615320304000_bib1","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.30416","article-title":"A prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"2026030615320304000_bib2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"2026030615320304000_bib3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/bloodadvances.2024014674","article-title":"Global outcomes and prognosis for relapsed\/refractory mature T-cell and NK-cell lymphomas: results from PETAL Consortium","volume":"9","author":"Han","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"2026030615320304000_bib4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood.2020010387","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026030615320304000_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000500666","article-title":"Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE Registry","volume":"143","author":"Lansigan","year":"2020","journal-title":"Acta Haematol"},{"issue":"7","key":"2026030615320304000_bib6","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"issue":"25","key":"2026030615320304000_bib7","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026030615320304000_bib8","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2026030615320304000_bib9","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1111\/bjh.20063","article-title":"Forecasting optimal treatments in relapsed\/refractory mature T- and NK-cell lymphomas: a global PETAL Consortium study","volume":"206","author":"Sorial","year":"2025","journal-title":"Br J Haematol"},{"issue":"7","key":"2026030615320304000_bib10","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00277-020-04025-2","article-title":"Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life","volume":"99","author":"Sortais","year":"2020","journal-title":"Ann Hematol"},{"issue":"11","key":"2026030615320304000_bib11","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026030615320304000_bib12","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.1038\/s41598-025-92963-0","article-title":"POD24-based prognostic signature enables personalized risk stratification in mantle cell lymphoma","volume":"15","author":"He","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"2026030615320304000_bib13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41408-025-01241-9","article-title":"Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study","volume":"15","author":"Sarkozy","year":"2025","journal-title":"Blood Cancer J"},{"issue":"36","key":"2026030615320304000_bib14","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","article-title":"International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma","volume":"35","author":"Maurer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026030615320304000_bib15","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.1997.15.2.528","article-title":"Outcome of patients with Hodgkin\u2019s disease failing after primary MOPP-ABVD","volume":"15","author":"Bonfante","year":"1997","journal-title":"J Clin Oncol"},{"issue":"16","key":"2026030615320304000_bib17","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2026030615320304000_bib16","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"25","key":"2026030615320304000_bib18","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1200\/JCO.23.00570","article-title":"Relapse timing is associated with distinct evolutionary dynamics in diffuse large B-cell lymphoma","volume":"41","author":"Hilton","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026030615320304000_bib19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/blood-2023-187254","article-title":"Epidemiology, clinical features and outcomes of peripheral T-cell lymphoma in Latin America [abstract]","volume":"142","author":"Fischer","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2026030615320304000_bib20","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/GO.21.00084","article-title":"Real-world data on adult T-cell leukemia\/lymphoma in Latin America: a study from the Grupo de Estudio Latinoamericano de Linfoproliferativos","volume":"7","author":"Malpica","year":"2021","journal-title":"JCO Glob Oncol"},{"issue":"4","key":"2026030615320304000_bib21","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1016\/S2352-3026(25)00011-0","article-title":"Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study","volume":"12","author":"Malpica","year":"2025","journal-title":"Lancet Haematol"},{"issue":"3","key":"2026030615320304000_bib22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"23","key":"2026030615320304000_bib23","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026030615320304000_bib24","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.3324\/haematol.2019.237990","article-title":"Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment","volume":"105","author":"Conconi","year":"2020","journal-title":"Haematologica"},{"key":"2026030615320304000_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00013","article-title":"Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non-small-cell lung cancer data set","volume":"3","author":"Griffith","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"issue":"11","key":"2026030615320304000_bib26","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026030615320304000_bib27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark analysis at the 25-year landmark point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"2026030615320304000_bib28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.1991.9.1.191","article-title":"Median follow-up in clinical trials","volume":"9","author":"Shuster","year":"1991","journal-title":"J Clin Oncol"},{"key":"2026030615320304000_bib29","author":"Rubin","year":"2004"},{"issue":"4","key":"2026030615320304000_bib30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"2026030615320304000_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.publhealth.20.1.145","article-title":"Time-dependent covariates in the Cox proportional-hazards regression model","volume":"20","author":"Fisher","year":"1999","journal-title":"Annu Rev Public Health"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/7\/755\/2503017\/blood_bld-2025-030149-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/7\/755\/2503017\/blood_bld-2025-030149-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:32:11Z","timestamp":1772829131000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/7\/755\/548172\/Early-time-to-relapse-as-a-survival-prognosticator"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,2,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030149","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,12]]},"published":{"date-parts":[[2026,2,12]]}}}